BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fukui H. Gut Microbiota and Host Reaction in Liver Diseases. Microorganisms. 2015;3:759-791. [PMID: 27682116 DOI: 10.3390/microorganisms3040759] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Tan Y, Li Y, Zhou F, Guo J, Wang T, Shi Y, Yang Y, Lu J, Pei G. Administration of a mixture of triterpenoids from yeyachun and phenolic acids from danshen ameliorates carbon tetrachloride-induced liver fibrosis in mice by the regulation of intestinal flora. Journal of Pharmacological Sciences 2020;143:165-75. [DOI: 10.1016/j.jphs.2020.04.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
2 Campion D, Giovo I, Ponzo P, Saracco GM, Balzola F, Alessandria C. Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosis. World J Hepatol 2019; 11(6): 489-512 [PMID: 31293718 DOI: 10.4254/wjh.v11.i6.489] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
3 Khalsa J, Duffy LC, Riscuta G, Starke-reed P, Hubbard VS. Omics for Understanding the Gut-Liver-Microbiome Axis and Precision Medicine. Clinical Pharmacology in Drug Development 2017;6:176-85. [DOI: 10.1002/cpdd.310] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
4 Kim H, Worsley O, Yang E, Purbojati RW, Liang AL, Tan W, Moses DID, Hartono S, Fan V, Lim TKH, Schuster SC, Foo RS, Chow PKH, Pettersson S. Persistent changes in liver methylation and microbiome composition following reversal of diet-induced non-alcoholic-fatty liver disease. Cell Mol Life Sci 2019;76:4341-54. [PMID: 31119300 DOI: 10.1007/s00018-019-03114-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
5 Pérez-Matute P, Íñiguez M, Villanueva-Millán MJ, Recio-Fernández E, Vázquez AM, Sánchez SC, Morano LE, Oteo JA. Short-term effects of direct-acting antiviral agents on inflammation and gut microbiota in hepatitis C-infected patients.Eur J Intern Med. 2019;67:47-58. [PMID: 31221551 DOI: 10.1016/j.ejim.2019.06.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
6 Al-Disi D, Ansari MGA, Sabico S, Wani K, Hussain SD, Elshafie MM, McTernan P, Al-Daghri NM. High glucose load and endotoxemia among overweight and obese Arab women with and without diabetes: An observational study. Medicine (Baltimore) 2020;99:e23211. [PMID: 33181703 DOI: 10.1097/MD.0000000000023211] [Reference Citation Analysis]
7 Glal KAM, Abd-Elsalam SM, Mostafa TM. Nitazoxanide versus rifaximin in preventing the recurrence of hepatic encephalopathy: A randomized double-blind controlled trial. J Hepatobiliary Pancreat Sci 2021. [PMID: 33768619 DOI: 10.1002/jhbp.947] [Reference Citation Analysis]
8 Yang R, Xu Y, Dai Z, Lin X, Wang H. The Immunologic Role of Gut Microbiota in Patients with Chronic HBV Infection. J Immunol Res 2018;2018:2361963. [PMID: 30148173 DOI: 10.1155/2018/2361963] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
9 Han M, Zhang T, Gu W, Yang X, Zhao R, Yu J. 2,3,5,4'-tetrahydroxy-stilbene-2-O-β-D-glucoside attenuates methionine and choline-deficient diet-induced non-alcoholic fatty liver disease. Exp Ther Med 2018;16:1087-94. [PMID: 30116360 DOI: 10.3892/etm.2018.6300] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
10 Fukui H. Leaky Gut and Gut-Liver Axis in Liver Cirrhosis: Clinical Studies Update. Gut Liver 2021;15:666-76. [PMID: 33071239 DOI: 10.5009/gnl20032] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
11 Shin NR, Bose S, Wang JH, Ansari A, Lim SK, Chin YW, Choi HS, Kim H. Flos Lonicera Combined with Metformin Ameliorates Hepatosteatosis and Glucose Intolerance in Association with Gut Microbiota Modulation. Front Microbiol. 2017;8:2271. [PMID: 29204141 DOI: 10.3389/fmicb.2017.02271] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
12 Yao X, Yu H, Fan G, Xiang H, Long L, Xu H, Wu Z, Chen M, Xi W, Gao Z, Liu C, Gong W, Yang A, Sun K, Yu R, Liang J, Xie B, Sun S. Impact of the Gut Microbiome on the Progression of Hepatitis B Virus Related Acute-on-Chronic Liver Failure. Front Cell Infect Microbiol 2021;11:573923. [PMID: 33889550 DOI: 10.3389/fcimb.2021.573923] [Reference Citation Analysis]
13 Qin C, Zhang H, Zhao L, Zeng M, Huang W, Fu G, Zhou W, Wang H, Yan H. Microbiota transplantation reveals beneficial impact of berberine on hepatotoxicity by improving gut homeostasis. Sci China Life Sci 2018;61:1537-44. [DOI: 10.1007/s11427-017-9202-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
14 Dornas W, Lagente V. Intestinally derived bacterial products stimulate development of nonalcoholic steatohepatitis. Pharmacol Res. 2019;141:418-428. [PMID: 30658094 DOI: 10.1016/j.phrs.2019.01.026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
15 Hoffmanová I, Sánchez D, Tučková L, Tlaskalová-Hogenová H. Celiac Disease and Liver Disorders: From Putative Pathogenesis to Clinical Implications. Nutrients 2018;10:E892. [PMID: 30002342 DOI: 10.3390/nu10070892] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
16 Fukui H. Improve gut microbiome: a new horizon of cancer therapy. Hepatobiliary Surg Nutr. 2017;6:424-428. [PMID: 29312982 DOI: 10.21037/hbsn.2017.08.04] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
17 Fukui H. Cytokines in Hepatic Injury. Liver Pathophysiology. Elsevier; 2017. pp. 341-54. [DOI: 10.1016/b978-0-12-804274-8.00027-8] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
18 Fukui H. Increased Intestinal Permeability and Decreased Barrier Function: Does It Really Influence the Risk of Inflammation? Inflamm Intest Dis 2016;1:135-45. [PMID: 29922669 DOI: 10.1159/000447252] [Cited by in Crossref: 110] [Cited by in F6Publishing: 102] [Article Influence: 18.3] [Reference Citation Analysis]
19 Liao J, Xie X, Gao J, Zhang Z, Qu F, Cui H, Cao Y, Han X, Zhao J, Wen W, Wang H. Jian-Gan-Xiao-Zhi Decoction Alleviates Inflammatory Response in Nonalcoholic Fatty Liver Disease Model Rats through Modulating Gut Microbiota. Evid Based Complement Alternat Med 2021;2021:5522755. [PMID: 33824675 DOI: 10.1155/2021/5522755] [Reference Citation Analysis]
20 Rocco A, Sgamato C, Compare D, Coccoli P, Nardone OM, Nardone G. Gut Microbes and Hepatic Encephalopathy: From the Old Concepts to New Perspectives. Front Cell Dev Biol 2021;9:748253. [PMID: 34900994 DOI: 10.3389/fcell.2021.748253] [Reference Citation Analysis]
21 Kassa Y, Million Y, Gedefie A, Moges F. Alteration of Gut Microbiota and Its Impact on Immune Response in Patients with Chronic HBV Infection: A Review. Infect Drug Resist 2021;14:2571-8. [PMID: 34262302 DOI: 10.2147/IDR.S305901] [Reference Citation Analysis]
22 Fukui H, Wiest R. Changes of Intestinal Functions in Liver Cirrhosis. Inflamm Intest Dis. 2016;1:24-40. [PMID: 29922655 DOI: 10.1159/000444436] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
23 Xu Y, Wang N, Tan HY, Li S, Zhang C, Feng Y. Function of Akkermansia muciniphila in Obesity: Interactions With Lipid Metabolism, Immune Response and Gut Systems. Front Microbiol 2020;11:219. [PMID: 32153527 DOI: 10.3389/fmicb.2020.00219] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 27.5] [Reference Citation Analysis]
24 Fukui H, Wiest R. Changes of Intestinal Functions in Liver Cirrhosis. Inflamm Intest Dis 2016;1:24-40. [PMID: 29922655 DOI: 10.1159/000444436] [Reference Citation Analysis]
25 Markowska E, Kiersztan A. Akkermansia muciniphila – obiecujący kandydat na probiotyk nowej generacji. Postępy Higieny i Medycyny Doświadczalnej 2021;75:724-48. [DOI: 10.2478/ahem-2021-0036] [Reference Citation Analysis]
26 Preveden T, Scarpellini E, Milić N, Luzza F, Abenavoli L. Gut microbiota changes and chronic hepatitis C virus infection. Expert Rev Gastroenterol Hepatol 2017;11:813-9. [PMID: 28621554 DOI: 10.1080/17474124.2017.1343663] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 8.4] [Reference Citation Analysis]
27 Urdaneta V, Casadesús J. Interactions between Bacteria and Bile Salts in the Gastrointestinal and Hepatobiliary Tracts. Front Med (Lausanne) 2017;4:163. [PMID: 29043249 DOI: 10.3389/fmed.2017.00163] [Cited by in Crossref: 115] [Cited by in F6Publishing: 92] [Article Influence: 23.0] [Reference Citation Analysis]
28 Hassouneh R, Bajaj JS. Gut Microbiota Modulation and Fecal Transplantation: An Overview on Innovative Strategies for Hepatic Encephalopathy Treatment. J Clin Med 2021;10:330. [PMID: 33477417 DOI: 10.3390/jcm10020330] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
29 Fukui H, Wiest R. Changes of Intestinal Functions in Liver Cirrhosis. Inflamm Intest Dis. 2016;1:24-40. [PMID: 29922655 DOI: 10.1159/000444436].] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Fukui H. Increased Intestinal Permeability and Decreased Barrier Function: Does It Really Influence the Risk of Inflammation? Inflamm Intest Dis. 2016;1:135-145. [PMID: 29922669 DOI: 10.1159/000447252.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Fukui H. Gut Microbiome-based Therapeutics in Liver Cirrhosis: Basic Consideration for the Next Step. J Clin Transl Hepatol 2017;5:249-60. [PMID: 28936406 DOI: 10.14218/JCTH.2017.00008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]